x

Posted 28 July, 2023

CATALYST PHARMACEUTICALS, INC. appointed new CEO

CEO Change detected for ticker Nasdaq:CPRX in a 8-K filed on 28 July, 2023.


  On July 24, 2023, Patrick J. McEnany, the Company's Chief Executive Officer ("CEO"), informed the Company's Board of Directors that he intends to retire as the Company's CEO by the end of 2023.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of CATALYST PHARMACEUTICALS, INC.
Health Care/Life Sciences • Pharmaceuticals
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
Market Cap
$1.97B
View Company Details
Relevant filing section
Item 5.02 
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 


On July 24, 2023, Patrick J. McEnany, the Company's Chief Executive Officer ("CEO"), informed the Company's Board of Directors that he intends to retire as the Company's CEO by the end of 2023. Mr. McEnany has agreed that he will continue to serve as the Company's CEO until his replacement is in place, and following his retirement as CEO, Mr. McEnany will continue to serve as the non-Executive Chairman of Catalyst's Board of Directors. In his letter to the Board confirming his decision to retire as the Company's CEO, Mr. McEnany reported that his decision to retire as the Company's CEO was not the result of any disagreements between Mr. McEnany, on the one hand, and the Company's management or Board of Directors, on the other hand, as to any matter relating to the Company's operations, finances, policies, or practices. 

The Board has retained a nationally recognized executive recruitment firm to initiate the search for Mr. McEnany's successor as CEO. 

On July 25, 2023, the Company issued a press release announcing that Mr. McEnany intends to retire, as discussed above. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.